gms | German Medical Science

61. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie

16. - 17.04.2015, Köln

Artikel

Artikel empfehlen

Identification of novel biomarkers for patients with renal cell carcinoma

Meeting Abstract

Suche in Medline nach

  • J. Ellinger - Universitätsklinikum Bonn, Urologie, Bonn, Germany
  • S. Schrödter - Universitätsklinikum Bonn, Urologie, Bonn, Germany
  • I. Syring - Universitätsklinikum Bonn, Urologie, Bonn, Germany
  • M. Deng - Universitätsklinikum Bonn, Urologie, Bonn, Germany
  • J. Blondeau - Universitätsklinikum Bonn, Urologie, Bonn, Germany
  • D. Schmidt - Universitätsklinikum Bonn, Urologie, Bonn, Germany
  • N. Klümper - Universitätsklinikum Bonn, Pathologie, Bonn, Germany
  • S. Perner - Universitätsklinikum Bonn, Pathologie, Bonn, Germany
  • S.C. Müller - Universitätsklinikum Bonn, Urologie, Bonn, Germany

Nordrhein-Westfälische Gesellschaft für Urologie. 61. Kongress der Nordrhein-Westfälischen Gesellschaft für Urologie. Köln, 16.-17.04.2015. Düsseldorf: German Medical Science GMS Publishing House; 2015. DocP2.6

doi: 10.3205/15nrwgu079, urn:nbn:de:0183-15nrwgu0797

Veröffentlicht: 13. März 2015

© 2015 Ellinger et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.

Gliederung

Text

Introduction: Renal cell carcinoma is one of the most common human malignancies. Despite of many efforts in the past, there is still no marker for diagnostic or prognostic purposes.

Methods: Microarray experiments were performed to determine the expression of 34,144 mRNA transcripts in 15 corresponding normal and malignant renal tissues. mRNA expression was validated using quantitative real-time PCR in 55 ccRCC and 52 normal renal specimen. siRNA mediated gene silencing was performed to study the functional relevance of dysregulated genes.

Results: We identified 1064 dysregulated transcripts (expression change >log2-fold; upregulated: 368, downregulated 696) in ccRCC tissue. Expression profiling allowed precise identification of ccRCC tissue based on a molecular signature. Dysregulation of 14 genes – so far not investigated in ccRCC – was confirmed using quantitative real-time PCR: upregulation of SLC6A3 (fold-change expression: mean 231-fold), NPTX2 (188-fold), TNFAIP6 (100-fold), NDUFA4L2 (78-fold), ENPP3 (42-fold), FABP6 (39-fold) and SPINK13 (26-fold), as well as downregulation of FXYD4 (2264-fold), SLC12A1 (863-fold), KNG1 (728-fold), NPHS2 (408-fold), SLC13A3 (68-fold), GCGR (27-fold), PLG (21-fold) in ccRCC tissue compared to normal renal tissue was observed. None of the investigated mRNAs was correlated with AJCC stage, pT-stage, metastasis nor grading (all p>0.03). mRNA levels were not correlated with RCC recurrence nor survival. siRNA-mediated knockdown of SLC6A3 and NDUFA4L2 did not influence cell proliferation.

Conclusion: We identified many novel mRNA transcripts dysregulated in ccRCC which may be useful as diagnostic biomarkers.